Pennsylvania (Independence Blue Cross) : As of January 1, 2025, IBX restricted Wegovy and Ozempic coverage to FDA-approved conditions (diabetes, heart disease), barring coverage for obesity or weightloss only
Two years after that, the agency approved another, Zepbound, for the same purpose
Anecdotal Health Benefits Although not yet fully backed by clinical studies, many patients exploring microdosing Semaglutide have shared encouraging results: Enhanced Mood: Some users report feeling more balanced emotionally, which could be linked to the effects of stabilized blood sugar and appetite regulation
When to Call a Doctor While most side effects are mild and improve over time, some symptoms require immediate medical attention
Novo Nordisks new drug IDegLira is a fixed-ratio combination of insulin degludec and the glucagonlike perptide-1 (GLP-1) agonist liraglutide